Selection and characterization of HER2/neu-binding affibody ligands

Protein Engineering, Design and Selection

Volumn 17, Issue 5, 2004, Pages 455-462

  Wikman, M ^a   Steffen, A C ^b   Gunneriusson, E ^c   Tolmachev, V ^b   Adams, G P ^d   Carlsson, J ^b   Stahl S ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Affibody AB   (Sweden)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Affibody; HER2; Ligand; Phage display; Selection

Indexed keywords

AFFIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; RADIOISOTOPE; STAPHYLOCOCCUS PROTEIN A; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOCARCINOMA; AFFINITY CHROMATOGRAPHY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOSENSOR; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG TARGETING; ESCHERICHIA COLI; GENE OVEREXPRESSION; ISOTOPE LABELING; NONHUMAN; OVARY CANCER; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ERBB-2; TIME FACTORS;

ESCHERICHIA COLI; STAPHYLOCOCCUS;

EID: 4644247278     PISSN: 17410126     EISSN: None     Source Type: Journal    
DOI: 10.1093/protein/gzh053     Document Type: Article

References (52)

1. Ballare, C., Barrio, M., Portela, P. and Mordoh, J. (1995) Cancer Immunol. Immunother., 41, 15-22.
2. Baselga, J. and Mendelsohn, J. (1994) Pharmacol. Ther., 64, 127-154.
3. Behr, T.M., Becker, W.S., Klein, M.W., Bair, H.J., Scheele, J.R. and Wolf, F.G. (1995) Cancer Res., 55, 5786s-5793s.
4. Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.M, Lee, T., Pope, S.H., Riordan, G.S. and Whitlow, M. (1988) Science, 242, 423-426.
5. Davies, J. and Riechmann, L. (1996) Protein Eng., 9, 531-537.
6. Desmyter, A., Spinelli, S., Payan, F., Lauwereys, M., Wyns, L., Muyldermans, S. and Cambillau, C. (2002) J. Biol. Chem., 277, 23645-23650.
7. Eklund, M, Axelsson, L., Uhlén, M. and Nygren, P.-Å. (2002) Proteins, 48, 454-462.
8. Fagerberg, J., Frodin, J.E., Ragnhammar, P., Steinitz, M., Wigzell, H. and Mellstedt, H. (1994) Cancer Immunol. Immunother., 38, 149-159.
9. Froidevaux, S., Heppeler, A., Eberle, A.N., Meier, A.M., Hausler, M., Beglinger, C., Behe, M., Powell, P. and Macke, H.R. (2000) Endocrinology, 141, 3304-3312.
10. Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Beraard-Marty, C., Piccart, M.J. and Larsimont, D. (2002) Ann. Oncol., 13, 1036-1043.
11. Garnett, M.C, Embleton, M.J., Jacobs, E. and Baldwin, R.W. (1985) Anticancer Drug Des., 1, 3-12.
12. Gräslund, T., Lundin, G., Uhlén, M., Nygren, P.-Å. and Hober, S. (2000) Protein Eng., 13, 703-709.
13. Gräslund, S., Eklund, M., Falk, R., Uhlén, M., Nygren, P.-Å. and Ståhl, S. (2002) J. Biotechnol., 99, 41-50.
14. Gunneriusson, E., Nord, K., Uhlén, M. and Nygren, P.-Å. (1999) Protein Eng., 12, 873-878.
15. Hansson, M., Ringdahl, J., Robert, A., Power, U., Goetsch, L., Nguyen, T.N., Uhlén, M., Ståhl, S. and Nygren, P.-Å. (1999) Immunotechnology, 4, 237-252.
16. Henning, P., Magnusson, M.K., Gunneriusson, E., Hong, S.S., Boulanger, P., Nygren, P.-Å. and Lindholm, L. (2002) Hum. Gene Ther., 13, 1427-1439.
17. Heppeler, A., Froidevaux, S., Eberle, A.N. and Maecke, H.R. (2000) Curr. Med. Chem., 7, 971-994.
18. Holliger, P., Prospero, T. and Winter, G. (1993) Proc. Natl Acad. Sci. USA, 90, 6444-6448.
19. Holt, L.J., Herring, C., Jespers, L.S., Woolven, B.P. and Tomlinson, I.M. (2003) Trends Biotechnol., 21, 484-490.
20. Horak, E.M., Heitner, T., Garrison, J.L., Simmons, H.H., Alpaugh, R.K., Amoroso, A.R., Marks, J.D., Weiner, L.M. and Adams, G.P. (2001) Proc. Am. Assoc. Cancer Res., 42, 774.
21. Huston, J.L., Levinson, D., Mudgett, H.M., Tai, M.S., Novotny, J., Margolies, M.N., Ridge, R.J., Bruccoleri, R.E., Haber, E., Crea, R. and Oppermann, H. (1988) Proc. Natl Acad. Sci. USA, 85, 5879-5883.
22. Karlström, A. and Nygren, P.-Å. (2001) Anal. Biochem., 295, 22-30.
23. Koide, A., Abbatiello, S., Rothgery, L. and Koide, S. (2002) Proc. Natl Acad. Sci. USA, 99, 1253-1258.
24. Kreitman, R.J. (1999) Curr. Opin. Immunol., 11, 570-578.
25. Natali, P.G., Nicotra, M.R., Bigotti, A., Venturo, I., Slamon, D.J., Fendly, B.M. and Ullrich, A. (1990) Int. J. Cancer, 45, 457-461.
26. Nilsson, B., Moks, T., Jansson, B., Abrahmsen, L., Elmblad, A., Holmgren, E., Henrichson, C., Jones, T.A. and Uhlén, M. (1987) Protein Eng., 1, 107-113.
27. Nilsson, F., Tarli, L., Viti, F. and Neri, D. (2000) Adv. Drug Deliv. Rev., 43, 165-196.
28. Nord, K., Nilsson, J., Nilsson, B., Uhlén, M. and Nygren, P.-Å. (1995) Protein Eng., 8, 601-608.
29. Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M. and Nygren, P.-Å. (1997) Nat. Biotechnol., 15, 772-777.
30. Nord, K., Gunneriusson, E., Uhlén, M. and Nygren, P.-Å. (2000) J. Biotechnol., 80, 45-54.
31. Nord, K., Nord, O., Uhlén, M., Kelley, B., Ljungqvist, C. and Nygren, P.-Å. (2001) Eur. J. Biochem., 268, 4269-4277.
32. Nygren, P.-Å. and Uhlén, M. (1997) Curr. Opin. Struct. Biol., 7, 463-469.
33. Orlova, A., Bruskin, A., Sjöström, A., Lundqvist, H., Gedda, L. and Tolmachev, V. (2000) Nucl. Med. Biol., 27, 827-835.
34. Press, M.F., Cordon-Cardo, C. and Slamon, D.J. (1990) Oncogene, 5, 953-962.
35. Rönnmark, J., Grönlund, H., Uhlén, M. and Nygren, P.-Å. (2002a) Eur. J. Biochem., 269, 2647-2655.
36. Rönnmark, J., Hansson, M., Nguyen, T., Uhlén, M., Robert, A., Ståhl, S. and Nygren, P.-Å. (2002b) J. Immunol. Methods, 261, 199-211.
37. Ruther, U. (1982) Nucleic Acids Res., 10, 5765-5772.
38. Sandström, K., Xu, Z., Forsberg, G. and Nygren, P.-Å. (2003) Protein Eng., 16, 691-697.
39. Skerra, A. (2000a) J. Mol. Recognit., 13, 167-187.
40. Skerra, A. (200Ob) Biochim. Biophys. Acta, 1482, 337-350.
41. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) Science, 235, 177-182.
42. Ståhl, S., Nilsson, J., Hober, S., Uhlén, M. and Nygren, P.-Å. (1999) In Flickinger, M.C. and Drew, S.W. (eds), The Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation: Affinity Fusions, Gene Expression. John Wiley and Sons Inc., New York, pp. 49-63.
43. Steplewski, Z., Lubeck, M.D. and Koprowski, H. (1983) Science, 221, 865-867.
44. Studier, F.W., Rosenberg, A.H., Dunn, J.J. and Dubendorff, J.W. (1990) Methods Enzymol., 185, 60-89.
45. Sundberg, A.L., Blomquist, E., Carlsson, J., Steffen, A.C. and Gedda, L. (2003) Nucl. Med. Biol., 30, 303-315.
46. Trauth, B.C., Klas, C., Peters, A.M., Matzku, S., Moller, P., Falk, W., Debatin, K.M. and Krammer, P.H. (1989) Science, 245, 301-305.
47. Ugur, O., Kostakoglu, L., Hui, E.T., Fisher, D.R., Garmestani, K., Gansow, O.A., Cheung, N.K. and Larson, S.M. (1996) Nucl. Med. Biol., 23, 1-8.
48. Wang, S.C. and Hung, M.C. (2001) Semin. Oncol., 28, 115-124.
49. Wilder, R.B., DeNardo, G.L. and DeNardo, S.J. (1996) J. Clin. Oncol., 14, 1383-1400.
50. Winter, G., Griffiths, A.D., Hawkins, R.E. and Hoogenboom, H.R. (1994) Annu. Rev. Immunol., 12, 433-455.
51. Xu, L. et al. (2002) Chem. Biol., 9, 933-942.
52. Yokota, T., Milenic, D.E., Whitlow, M. and Schlom, J. (1992) Cancer, 52, 3402-3408.